25
Apr
London [United Kingdom], April 25: At the Charing Cross Symposium 2026 this week, one theme kept resurfacing in quiet conversations between clinicians: what happens after the first year? It’s a question that doesn’t always make headlines, but it tends to shape real-world decisions. The preliminary three-year data from the SIRONA randomised trial, presented by Prof. Ulf Teichgräber, leaned directly into that gap. The study, backed by Concept Medical Inc., compares sirolimus-coated and paclitaxel-coated balloon angioplasty in femoropopliteal artery disease — an area where treatment choices have long been influenced by familiarity as much as by evidence. Looking Past the First…
